Charlie Fazio, MD, senior vice president and medical director of HealthPartners discusses the uncertainty felt by practices as the industry moves from fee-for-service to value-based care.
Charlie Fazio, MD, senior vice president and medical director of HealthPartners discusses the uncertainty felt by practices as the industry moves from fee-for-service to value-based care
Transcript (slightly modified)
How do physicians balance the fact that the industry is moving toward value-based care, but they are mostly still practicing in a fee-for-service environment?
There’s a lot of uncertainty as people live in a fee-for-service world and we start to talk about a world where there might be more payments based on population. It’s tough for a practice to figure out "when do I go from A to B?" and so for a while they live with the ambiguity, they try to run both models even though at the same time, I want to treat everybody I see in the course of a day, the same way, according to the same model, without worrying about how I’m being paid for them. You can’t possibly keep track of all that.
So, in a lot of ways I think it’s important for a practice to think through: how do I coordinate the various contracts I have? How do I move more in the direction of population-based care? When will it be safe for me to think through: I want to run this as efficiently as I can, I want to run this based on cost rather than on revenue, and I want to go all-in on the team version.
That’s a tough decision and I think it’s incumbent on all of us. It’s important to all of us and we’ll all benefit from helping practices figure out how to go there.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More